These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 28389027

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. [18F]fluciclovine vs. [18F]fluorocholine Positron Emission Tomography/Computed Tomography: A Head-to-Head Comparison for Early Detection of Biochemical Recurrence in Prostate Cancer Patients.
    Ferrari C, Mammucci P, Lavelli V, Pisani AR, Nappi AG, Rubini D, Sardaro A, Rubini G.
    Tomography; 2022 Nov 05; 8(6):2709-2722. PubMed ID: 36412685
    [Abstract] [Full Text] [Related]

  • 23. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C, Zhu Y, Su H, Xu X, Zhang Y, Ye D, Hu S.
    Prostate; 2018 Dec 05; 78(16):1215-1221. PubMed ID: 30027591
    [Abstract] [Full Text] [Related]

  • 24. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of 68Ga-PSMA-11 when 18F-fluorocholine is non-contributive].
    Gauthé M, Belissant O, Girard A, Zhang Yin J, Ohnona J, Cottereau AS, Nataf V, Balogova S, Pontvert D, Lebret T, Guillonneau B, Cussenot O, Talbot JN.
    Prog Urol; 2017 Dec 05; 27(8-9):474-481. PubMed ID: 28576423
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J, Even-Sapir E, Ben-Haim S, Saad A, Spieler B, Davidson T, Berger R, Weiss I, Appel S, Lawrence YR, Symon Z.
    Am J Clin Oncol; 2017 Jun 05; 40(3):256-259. PubMed ID: 25319322
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, Messa C.
    Clin Nucl Med; 2012 Apr 05; 37(4):325-31. PubMed ID: 22391699
    [Abstract] [Full Text] [Related]

  • 34. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R.
    BJU Int; 2017 Aug 05; 120(2):197-203. PubMed ID: 27981732
    [Abstract] [Full Text] [Related]

  • 35. Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
    Mena E, Rowe SP, Shih JH, Lindenberg L, Turkbey B, Fourquet A, Lin FI, Adler S, Eclarinal P, McKinney YL, Citrin DE, Dahut W, Wood BJ, Chang R, Levy E, Merino M, Gorin MA, Pomper MG, Pinto PA, Eary JF, Choyke PL, Pienta KJ.
    J Nucl Med; 2022 Aug 05; 63(8):1184-1190. PubMed ID: 34916246
    [Abstract] [Full Text] [Related]

  • 36. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations.
    Chevalme YM, Boudali L, Gauthé M, Rousseau C, Skanjeti A, Merlin C, Robin P, Giraudet AL, Janier M, Talbot JN.
    Eur J Nucl Med Mol Imaging; 2021 Aug 05; 48(9):2935-2950. PubMed ID: 33416958
    [Abstract] [Full Text] [Related]

  • 37. Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy.
    Oderda M, Joniau S, Palazzetti A, Falcone M, Melloni G, Van Den Bossche H, Deconinck S, Zattoni F, Karnes RJ, Gontero P.
    Eur Urol Focus; 2018 Mar 05; 4(2):288-293. PubMed ID: 30205893
    [Abstract] [Full Text] [Related]

  • 38. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Barbaud M, Frindel M, Ferrer L, Le Thiec M, Rusu D, Rauscher A, Maucherat B, Baumgartner P, Fleury V, Colombié M, Thierry-Morel A, Kraeber-Bodéré F, Campion L, Rousseau C.
    Prostate; 2019 Apr 05; 79(5):454-461. PubMed ID: 30549066
    [Abstract] [Full Text] [Related]

  • 39. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
    von Eyben FE, Kairemo K.
    Ann Nucl Med; 2016 Jul 05; 30(6):385-92. PubMed ID: 27173771
    [Abstract] [Full Text] [Related]

  • 40. Towards improved diagnosis: radiomics and quantitative biomarkers in 18 F-PSMA-1007 and 18 F-fluorocholine PET/CT for prostate cancer recurrence.
    Panagiotidis E, Andreou S, Paschali A, Angeioplasti K, Vlontzou E, Kalathas T, Pipintakou A, Fothiadaki A, Makridou A, Chatzimarkou M, Papanastasiou E, Datseris I, Chatzipavlidou V.
    Nucl Med Commun; 2024 Sep 01; 45(9):796-803. PubMed ID: 38832429
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.